Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Teva (Details) - Teva - USD ($) $ in Millions	3 Months Ended	9 Months Ended
Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Reimbursement of research and development expenses
Disaggregation of Revenue [Line Items]
Reduction of Research and development expense	$ 25.9	$ 34.2	$ 82.1	$ 102.9
Amounts recognized in connection with up-front and development milestone payments received
Disaggregation of Revenue [Line Items]
Other operating income	$ 17.2	$ 22.8	$ 54.5	$ 68.8

The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Name:	us-gaap_OtherOperatingIncome
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration